Related Experiment Videos
[The mutagenicity evaluation of MT-141, a new cephamycin]
Abstract:
Mutagenicity of MT-141, a new cephamycin, was evaluated by in vitro and in vivo assays. MT-141 did not induce mutations of the test strains, Escherichia coli WP2 (uvr A) and Salmonella typhimurium TA1535, TA1537, TA1538, TA100 and TA98, with and without metabolic activation in vitro. In bone marrow micronucleus assay with male mice, MT-141 showed no induction of micronucleated polychromatic erythrocyte at 6 hours and 30 hours after administration. In addition MT-141 was found not to cause any dominant lethal effects on male mice for 8 weeks after administration.
Insights
The new cephamycin, MT-141, demonstrated no mutagenicity in bacterial assays or in vivo micronucleus tests in mice. MT-141 also showed no dominant lethal effects, indicating a lack of genotoxicity.
Area of Science:
- Microbiology
- Toxicology
- Pharmacology
Background:
- Cephamycins are a class of beta-lactam antibiotics.
- Assessing the mutagenicity of new drug candidates is crucial for safety.
- MT-141 is a novel cephamycin antibiotic.
Purpose of the Study:
- To evaluate the mutagenicity of the new cephamycin, MT-141.
- To determine if MT-141 poses a genotoxic risk.
- To assess the safety profile of MT-141.
Main Methods:
- In vitro bacterial mutagenicity assays using Escherichia coli and Salmonella typhimurium strains.
- In vivo bone marrow micronucleus assay in male mice.
- In vivo dominant lethal assay in male mice.
Main Results:
- MT-141 did not induce mutations in bacterial strains with or without metabolic activation.
- No induction of micronucleated polychromatic erythrocytes was observed in mice.
- MT-141 did not cause dominant lethal effects in male mice over an 8-week period.
Conclusions:
- MT-141 exhibits no mutagenic potential in vitro.
- MT-141 is not genotoxic in vivo based on micronucleus and dominant lethal assays.
- The evaluated assays suggest MT-141 has a favorable safety profile regarding mutagenicity.